Literature DB >> 10608495

The breast cancer prevention trial: should women at risk take tamoxifen?

V A McKeon1.   

Abstract

Tamoxifen is nonsteroidal antiestrogen originally developed in 1996 as a contraceptive. Recently, tamoxifen has been under study within the massive Breast Cancer Prevention Trial-but have we learned enough to recommend tamoxifen for breast cancer prevention? This article looks at the drug therapies, including tamoxifen, currently under development for fighting and preventing breast cancer.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10608495

Source DB:  PubMed          Journal:  J Obstet Gynecol Neonatal Nurs        ISSN： 0090-0311


  2 in total

1.  The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy.

Authors:  Theodossis A Theodossiou; Cathrine E Olsen; Marte Jonsson; Andreas Kubin; John S Hothersall; Kristian Berg
Journal:  Redox Biol       Date:  2017-02-24       Impact factor: 11.799

2.  Equol enhances tamoxifen's anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells.

Authors:  Christiana Charalambous; Chara A Pitta; Andreas I Constantinou
Journal:  BMC Cancer       Date:  2013-05-15       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.